POLB001 CRS Patent Granted in South Korea

AI SummaryClose X

Poolbeg Pharma PLC has announced the formal granting of a South Korean patent for its POLB 001, a p38 MAP kinase inhibitor intended to prevent cancer immunotherapy-associated Cytokine Release Syndrome (CRS). This patent, with a default expiry of 2044, strengthens the company's intellectual property portfolio for POLB 001, which has already secured patents in Europe, Canada, and Australia. The company views this expansion of its patent estate as crucial for enhancing POLB 001's value and attractiveness to potential pharmaceutical partners, particularly in the strategically important area of cancer immunotherapy.

Disclaimer*

UK 100

Latest directors dealings